These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 26177715)
1. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease. Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715 [TBL] [Abstract][Full Text] [Related]
2. The informant AD8 is superior to participant AD8 in detecting cognitive impairment in a memory clinic setting. Dong Y; Pang WS; Lim LB; Yang YH; Morris JC; Hilal S; Venketasubramanian N; Chen CL J Alzheimers Dis; 2013; 35(1):159-68. PubMed ID: 23380993 [TBL] [Abstract][Full Text] [Related]
3. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic. Clarnette R; O'Caoimh R; Antony DN; Svendrovski A; Molloy DW Int J Geriatr Psychiatry; 2017 Jun; 32(6):643-649. PubMed ID: 27427212 [TBL] [Abstract][Full Text] [Related]
5. The reliability and validity of the informant AD8 by comparison with a series of cognitive assessment tools in primary healthcare. Shaik MA; Xu X; Chan QL; Hui RJ; Chong SS; Chen CL; Dong Y Int Psychogeriatr; 2016 Mar; 28(3):443-52. PubMed ID: 26489991 [TBL] [Abstract][Full Text] [Related]
6. The Informant AD8 Can Discriminate Patients with Dementia From Healthy Control Participants in an Asian Older Cohort. Kan CN; Zhang L; Cheng CY; Wong TY; Venketasubramanian N; Chen CL; Xu X J Am Med Dir Assoc; 2019 Jun; 20(6):775-779. PubMed ID: 30661859 [TBL] [Abstract][Full Text] [Related]
7. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease. Hendershott TR; Zhu D; Llanes S; Poston KL Parkinsonism Relat Disord; 2017 May; 38():31-34. PubMed ID: 28215728 [TBL] [Abstract][Full Text] [Related]
8. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Memória CM; Yassuda MS; Nakano EY; Forlenza OV Int J Geriatr Psychiatry; 2013 Jan; 28(1):34-40. PubMed ID: 22368034 [TBL] [Abstract][Full Text] [Related]
10. Validation of an informant-based cognitive screening tool for Parkinson disease. Chee KY; Ong KY; Mak CY; Yacob S; Yeo SC; Thrichelam N; Amarnath DD; Thong KS; Moey CH; Ponusamy T; Viswanathan S; Puvanarajah S Asia Pac Psychiatry; 2017 Dec; 9(4):. PubMed ID: 28326670 [TBL] [Abstract][Full Text] [Related]
11. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting. Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705 [TBL] [Abstract][Full Text] [Related]
12. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease. Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127 [TBL] [Abstract][Full Text] [Related]
13. The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. Pirogovsky E; Schiehser DM; Litvan I; Obtera KM; Burke MM; Lessig SL; Song DD; Liu L; Filoteo JV Parkinsonism Relat Disord; 2014 Jun; 20(6):627-31. PubMed ID: 24709086 [TBL] [Abstract][Full Text] [Related]
14. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230 [TBL] [Abstract][Full Text] [Related]
15. Determining an appropriate cutting score for indication of impairment on the Montreal Cognitive Assessment. Waldron-Perrine B; Axelrod BN Int J Geriatr Psychiatry; 2012 Nov; 27(11):1189-94. PubMed ID: 22228412 [TBL] [Abstract][Full Text] [Related]
16. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Godefroy O; Fickl A; Roussel M; Auribault C; Bugnicourt JM; Lamy C; Canaple S; Petitnicolas G Stroke; 2011 Jun; 42(6):1712-6. PubMed ID: 21474808 [TBL] [Abstract][Full Text] [Related]
17. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Dalrymple-Alford JC; MacAskill MR; Nakas CT; Livingston L; Graham C; Crucian GP; Melzer TR; Kirwan J; Keenan R; Wells S; Porter RJ; Watts R; Anderson TJ Neurology; 2010 Nov; 75(19):1717-25. PubMed ID: 21060094 [TBL] [Abstract][Full Text] [Related]
19. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Fujiwara Y; Suzuki H; Yasunaga M; Sugiyama M; Ijuin M; Sakuma N; Inagaki H; Iwasa H; Ura C; Yatomi N; Ishii K; Tokumaru AM; Homma A; Nasreddine Z; Shinkai S Geriatr Gerontol Int; 2010 Jul; 10(3):225-32. PubMed ID: 20141536 [TBL] [Abstract][Full Text] [Related]